Elicio Therapeutics, Inc. announced new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P. The preliminary data showed patients receiving ELI-002 7P at the Phase 2 dose of 4.9mg AMP-peptide were yet to reach the median disease-free survival ("DFS") endpoint as of the May 24, 2024 data cutoff date. These findings replicate the results in the AMPLIFY-2P trial of similar patients published in Nature Medicine.

The company look forward to providing additional clinical data updates from the AMPLIFY Phase 1 trials expected later in 2024 and the randomized Phase 2 interim analysis expected in first quarter of 2025.